You are here: Industry Insights > crizanlizumab

News List

FDA grants breakthrough therapy status to crizanlizumab pharmaceutical-technology
January 10, 2019
Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the use of crizanlizumab (SEG101) to prevent vaso-occlusive crises (VOCs) in sickle cell disease (SCD) patients of all genotypes.
FDA grants breakthrough therapy status to crizanlizumab pharmaceutical-technology
January 10, 2019
Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the use of crizanlizumab (SEG101) to prevent vaso-occlusive crises (VOCs) in sickle cell disease (SCD) patients of all genotypes.....
Crizanlizumab Receives FDA Breakthrough Therapy Designation americanpharmaceuticalreview
January 09, 2019
Novartis announced the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of .....
Novartis Announces New Crizanlizumab Data Analysis in Sickle Cell Disease americanpharmaceuticalreview
December 04, 2018
New data from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab -- a once-a-month, humanized anti-P-selectin monoclonal antibody infusion being investigated.....
Novartis crizanlizumab shows promise in sickle cell anaemia pharmatimes
October 11, 2018
A new analysis has shown that Novartis’ crizanlizumab reduced the number of patients with sickle cell disease experiencing a pain crisis.